|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The anti-obesity drugs market was valued at about USD 1,690 million in 2020, and it is expected to reach USD 4,250 million in 2026, registering a CAGR of 15% over the forecast period, 2021-2026.
During the COVID-19 situation, it was observed that obesity had increased exponentially. As per an article published by the European Journal of Nutrition in December 2020, the rate of obesity has increased in the world. The major reason being a change in lifestyle and a decrease in exercise practice among people as they avoided gym and yoga classes due to the social distancing protocols. This increase in the obesity population is expected to drive the demand for anti-obesity drugs in the near future.
According to a report published by Our World in Data in 2017, 13% of adults in the world are obese, and 39% of all adults in the world are overweight. One in five children and adolescents globally are overweight. Incidences of obesity have been increasing fiercely over the past decades, and it is often described as a global endemic, especially in the developed countries where lifestyle-related disorders, such as anxiety, stress, smoking, and drinking, are more prevalent.
Owing to the increase in the obesity population worldwide, the key players in the market are also undergoing product developments and seeking market approvals. For instance, in 2018, a Danish pharma company, Novo Nordisk, entered a strategic partnership with Evotec AG to discover and develop drug molecules to treat several metabolic disorders, including obesity, diabetes, and other associated disorders. Later, in December 2020, Novo Nordisk submitted a marketing authorization application to the European Medicines Agency (EMA) seeking approval for a once-weekly semaglutide for weight management.
In addition, research on several potential drug molecules that target both obesity and Type 2 diabetes mellitus has become a key trend among the anti-obesity market players. The increasing epidemic of obesity and Type 2 diabetes is encouraging researchers and vendors in the market to research drugs that can counter both obesity and Type 2 diabetes. Hence, the increasing obese population and rise in unhealthy eating habits and sedentary lifestyles are expected to drive the market growth over the forecast period.
However, the availability of alternative therapies and the potential side effects of anti-obesity drugs are expected to restrain the market growth.
Scope of the Report
As per the scope of the report, anti-obesity drugs or weight loss medications are pharmacological agents that reduce or control weight. These medications alter one of the fundamental processes of the human body, weight regulation, by altering either appetite or absorption of calories. The anti-obesity drugs market is segmented by mechanism of action (peripherally acting drugs and centrally acting drugs), drug type (prescription drugs and OTC drugs), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the market size and forecasts in value (USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally.
|By Mechanism of Action|
|Peripherally Acting Drugs|
|Centrally Acting Drugs|
|By Drug Type|
Key Market Trends
The Prescription Drugs Segment is Expected to Exhibit a Better Growth Rate over the Forecast Period
By drug type, the prescription drugs segment is expected to hold a significant market share. In the current COVID-19 scenario, various companies have been exploring new classes of medicines that help people lose weight and control diabetes as a potential in fighting the pandemic disease, as COVID-19 has severe consequences in the obese population. In September 2020, Novo Nordisk AS announced that it is performing research on GLP-1 drug used for obesity in COVID-19 patients. Such research and development activities are expected to propel the demand for prescription drugs. Moreover, the rising intake of junk foods/fast foods is resulting in declining health among the population worldwide, leading to an increase in the prevalence of obesity, especially in some developed parts of the world. For instance, in the United States, from 1999–2000 and 2017–2018, the prevalence of obesity increased from 30.5% to 42.4%, and the prevalence of severe obesity increased from 4.7% to 9.2%, as per the 2018 report by the Centers for Disease Control and Prevention.
In June 2020, China Medical System Holdings signed a USD 400 million-plus agreement for Chinese commercialization rights to US biotech company Gelesis Inc.’s prescription obesity management product, Plenty. All these developments by the players, coupled with increasing awareness of prescription medicine, are anticipated to boost the growth of the prescription drugs segment.
To understand key trends, Download Sample Report
North America is Expected to Dominate the Market over the Forecast Period
North America is expected to dominate the global anti-obesity drugs market. The primary factors driving the growth of the market studied are the increase in the obese population and high healthcare spending.
In September 2020, the Centers for Disease Control and Prevention (CDC) notified that adult obesity prevalence is increasing and racial and ethnic disparities persist owing to the current circumstances of work from home, less physical activities, and financial and other stress among the adult population. The CDC stated that obesity remains high, and currently, twelve states have an adult obesity prevalence at or above 35%, including Alabama, Arkansas, Indiana, Kansas, Kentucky, Louisiana, Michigan, Mississippi, Oklahoma, South Carolina, Tennessee, and West Virginia, which is high as compared to 2018, when nine states reported 35% obese population.
Also, according to the finding of CDC in 2017-18, the age-adjusted prevalence of obesity in adults was 42.4%, and there were no significant differences between men and women among all adults or by age group. Also, as per the data published by the Organization for Economic Co-operation and Development, in Canada, 59.1% of the population aged 15 years or more was obese, whereas, in Mexico, 75.2% of the population aged 15 years or more was obese in 2017- 2018.
The high obesity rate has always attracted the key players to make developments in the region. For instance, in 2020, Kintai Therapeutics, a US-headquartered company, announced that it was working across therapeutic areas and is beginning IND-enabling studies for its first potential therapeutic for the treatment of obesity. The first drug candidate is KTX-0200, which has demonstrated sustained weight loss and improvements in other markers of health in animal models. The launch of these pipeline products and the increasing geographic footprints of the players are expected to propel the market growth in this region.
To understand geography trends, Download Sample Report
The presence of major market players, such as GlaxoSmithKline PLC, Novo Nordisk AS, Pfizer Inc., F Hoffmann-La Roche AG, and Bayer AG, is increasing the overall competitive rivalry of the market. The key players are focused on inorganic growth strategies such as collaborating with successful personalities and initiatives or programs at the national levels, which promote their products. Therefore, these are recognized earlier than other brands in the market studied. With the high prevalence rate of the disease, the intensity of competitive rivalry is moderate to high.
In January 2021, Novartis AG announced the results of its Phase II trial of the investigational product drug called Bimagrumab. The drug has shown potential for the indication in obesity. The drug is currently being studied in the Novartis pipeline.
In January 2021, Novo Nordisk AS signed a partnership with the start-up Fauna Bio to identify new therapeutic approaches to obesity by studying the molecules and pathways that regulate metabolism in hibernating animals.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Obesity and Related Chronic Diseases
4.2.2 Growing Unhealthy and Sedentary Lifestyles
4.3 Market Restraints
4.3.1 Availability of Alternative Treatment Options
4.3.2 Side Effects of Drugs
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Mechanism of Action
5.1.1 Peripherally Acting Drugs
5.1.2 Centrally Acting Drugs
5.2 By Drug Type
5.2.1 Prescription Drugs
5.2.2 OTC Drugs
5.3.1 North America
126.96.36.199 United States (By Mechanism of Action and Drug Type)
188.8.131.52 Canada (By Mechanism of Action and Drug Type)
184.108.40.206 Mexico (By Mechanism of Action and Drug Type)
220.127.116.11 United Kingdom (By Mechanism of Action and Drug Type)
18.104.22.168 Germany (By Mechanism of Action and Drug Type)
22.214.171.124 France (By Mechanism of Action and Drug Type)
126.96.36.199 Italy (By Mechanism of Action and Drug Type)
188.8.131.52 Spain (By Mechanism of Action and Drug Type)
184.108.40.206 Rest of Europe (By Mechanism of Action and Drug Type)
220.127.116.11 China (By Mechanism of Action and Drug Type)
18.104.22.168 Japan (By Mechanism of Action and Drug Type)
22.214.171.124 India (By Mechanism of Action and Drug Type)
126.96.36.199 Australia (By Mechanism of Action and Drug Type)
188.8.131.52 South Korea (By Mechanism of Action and Drug Type)
184.108.40.206 Rest of Asia-Pacific (By Mechanism of Action and Drug Type)
5.3.4 Middle-East and Africa
220.127.116.11 GCC (By Mechanism of Action and Drug Type)
18.104.22.168 South Africa (By Mechanism of Action and Drug Type)
22.214.171.124 Rest of Middle-East and Africa (By Mechanism of Action and Drug Type)
5.3.5 South America
126.96.36.199 Brazil (By Mechanism of Action and Drug Type)
188.8.131.52 Argentina (By Mechanism of Action and Drug Type)
184.108.40.206 Rest of South America (By Mechanism of Action and Drug Type)
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Arena Pharmaceuticals Inc.
6.1.3 Bayer AG
6.1.4 Bristol-Myers Squibb
6.1.5 Currax Pharmaceuticals LLC
6.1.6 Eisai Co. Ltd
6.1.7 F. Hoffmann-La Roche AG
6.1.8 GlaxoSmithKline PLC
6.1.9 Merck & Co. Inc.
6.1.10 Norgine BV
6.1.11 Novo Nordisk AS
6.1.12 Orexigen Therapeutics
6.1.13 Pfizer Inc.
6.1.14 Rhythm Pharmaceuticals
6.1.15 Takeda Pharmaceuticals
6.1.16 Vivus Inc.
6.1.18 Zydus Cadila
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Anti-obesity Drugs Market market is studied from 2018 - 2026.
What is the growth rate of Global Anti-obesity Drugs Market?
The Global Anti-obesity Drugs Market is growing at a CAGR of 15% over the next 5 years.
Which region has highest growth rate in Global Anti-obesity Drugs Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Anti-obesity Drugs Market?
North America holds highest share in 2020.
Who are the key players in Global Anti-obesity Drugs Market?
Vivus, F Hoffmann-La Roche AG, GlaxoSmithKline PLC, Novo Nordisk AS, Currax Pharmaceuticals LLC are the major companies operating in Global Anti-obesity Drugs Market.